Morgan Stanley analyst Michael Ha raised the firm’s price target on Humana to $637 from $620 and keeps an Overweight rating on the shares, arguing that the company has "the strongest earnings growth story in Managed Care through 2025." Management is targeting $37 EPS by 2025, but the firm believes Humana can achieve a 17% compound annual growth rate to $40 EPS by 2025 with room for potential upside, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HUM:
- Morgan Stanley says Humana could trade up by mid-single digits on final MA rates
- Final Medicare Advantage rates positive for managed care, says JPMorgan
- Ohio AG Yost sues Express Scripts, Prime Therapeutics over drug price fixing
- Cigna, Humana accused of price fixing by Ohio attorney general, WSJ reports
- Humana stock a bet on healthcare for seniors, Barron’s says